Tag:

Sanofi

Latest Headlines

Latest Headlines

Sanofi leads $11M Series A round for needle-free delivery company

Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.

FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine

Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.

Amgen sues to block Sanofi and Regeneron at the PCSK9 goal line

Sanofi and Regeneron have cut to the front of the line in the race to develop a new class of cardio drugs, but now rival Amgen has made a chess move of its own, filing a patent-infringement lawsuit designed to block its rivals from reaching what's expected to be a blockbuster market.

Sanofi inks pact with Immune Design to boost herpes vax effort

Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.

Sanofi, Selecta join hands in diabetes vaccine push

Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.

Sanofi takes rotavirus vax into Phase III with eye on Indian market

India's rotavirus vaccines market is headed for a shake-up, and Sanofi's angling to get in on the action. It got one step closer this week, with its Indian affiliate commencing Phase III clinical trials for its own investigational vaccine.

Sanofi wins kudos for airing bribery probe. Phase II? Take to social media

Last week, Sanofi told the feds it had hired an outside law firm to dive into an anonymous whistleblower's accusations of corruption in the Middle East. But the company's proactive approach may not be enough to block a blow to its reputation, experts say.

Alnylam trumpets early promise for its Sanofi-partnered RNAi drug

Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.

Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant

As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.

Sanofi joins list of Big Pharmas fielding bribery allegations

Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.